Alu­mis clos­es a $259M Se­ries C to back its TYK2, flirts with talk about an IPO

As it pre­pares to launch Phase III stud­ies of its TYK2 in­hibitor, im­munol­o­gy start­up Alu­mis has raised a $259 mil­lion Se­ries C round that will fund the late-stage tri­als in mod­er­ate-to-se­vere plaque pso­ri­a­sis.

Alu­mis said piv­otal stud­ies for its drug ESK-001 will be­gin in the sec­ond half of this year. The Fore­site Labs-in­cu­bat­ed biotech hopes that the ex­per­i­men­tal ther­a­py could com­pete with Bris­tol My­ers Squibb’s So­tyk­tu and an up­com­ing drug from Take­da that was at the heart of one of last year’s biggest li­cens­ing deals.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER